Share this post on:

Product: AK-7

VPS13B RNAi Summary

Specificity
protocadherin beta 19 pseudogene (PCDHB19P) on chromosome 5
Gene
VPS13B

Applications/Dilutions

Application Notes
This RNAi causes protein knockdown.

Packaging, Storage & Formulations

Storage
Store at -20C. Avoid freeze-thaw cycles.

Notes

This product is produced by and distributed for Abnova, a company based in Taiwan.

Alternate Names for VPS13B RNAi

  • cohen syndrome protein 1
  • DKFZp313I0811
  • KIAA0532
  • vacuolar protein sorting 13 homolog B (yeast)

Background

Chimera RNA interference (chimera RNAi) is process by which small interfering RNA/DNA chimera triggers the destruction of mRNA for the original gene.  The discovery work, design, and application of chimera RNAi has been pioneered by Professor Kaoru Saigo and Dr. Kumiko Ui-Tei at the University of Tokyo.  Chimera RNAi has many advantages over the conventional siRNAs.  First, it has been demonstrated to have reliable knock-down for over 10,000 human genes.  Because the human genome is composed of an intricate, genetic network, chimera RNAis unique design has successfully obviated the off-target effects including microRNA-based influence.  Another advantage of the chimera RNAi technology is its effectiveness at low concentrations (0.5nM to 5nM); only mRNA is destroyed so genomic genes are not affected.  Finally, having both the sense and anti-sense strands consisting RNA/DNA chimera, it offers much greater compound stability for streamlining in vitro and in vivo assays and applications while minimizing interferon induction and other adverse reactions.

PMID: 23482747

Share this post on:

Author: Potassium channel

Share this post on:

Product: N-[(6-Aminophenyl)methyl]adenosine

VPS13B RNAi Summary

Specificity
major histocompatibility complex, class II, DR beta 6 (pseudogene) (HLA-DRB6) on chromosome 6
Gene
VPS13B

Applications/Dilutions

Application Notes
This RNAi causes protein knockdown.

Packaging, Storage & Formulations

Storage
Store at -20C. Avoid freeze-thaw cycles.

Notes

This product is produced by and distributed for Abnova, a company based in Taiwan.

Alternate Names for VPS13B RNAi

  • cohen syndrome protein 1
  • DKFZp313I0811
  • KIAA0532
  • vacuolar protein sorting 13 homolog B (yeast)

Background

Chimera RNA interference (chimera RNAi) is process by which small interfering RNA/DNA chimera triggers the destruction of mRNA for the original gene.  The discovery work, design, and application of chimera RNAi has been pioneered by Professor Kaoru Saigo and Dr. Kumiko Ui-Tei at the University of Tokyo.  Chimera RNAi has many advantages over the conventional siRNAs.  First, it has been demonstrated to have reliable knock-down for over 10,000 human genes.  Because the human genome is composed of an intricate, genetic network, chimera RNAis unique design has successfully obviated the off-target effects including microRNA-based influence.  Another advantage of the chimera RNAi technology is its effectiveness at low concentrations (0.5nM to 5nM); only mRNA is destroyed so genomic genes are not affected.  Finally, having both the sense and anti-sense strands consisting RNA/DNA chimera, it offers much greater compound stability for streamlining in vitro and in vivo assays and applications while minimizing interferon induction and other adverse reactions.

PMID: 15312648

Share this post on:

Author: Potassium channel

Share this post on:

Product: Mulberroside A

VPS13B RNAi Summary

Specificity
vacuolar protein sorting 13B (yeast) (VPS13B), transcript variant 4, mRNA
Gene
VPS13B

Applications/Dilutions

Application Notes
This RNAi causes protein knockdown.

Packaging, Storage & Formulations

Storage
Store at -20C. Avoid freeze-thaw cycles.

Notes

This product is produced by and distributed for Abnova, a company based in Taiwan.

Alternate Names for VPS13B RNAi

  • cohen syndrome protein 1
  • DKFZp313I0811
  • KIAA0532
  • vacuolar protein sorting 13 homolog B (yeast)

Background

Chimera RNA interference (chimera RNAi) is process by which small interfering RNA/DNA chimera triggers the destruction of mRNA for the original gene.  The discovery work, design, and application of chimera RNAi has been pioneered by Professor Kaoru Saigo and Dr. Kumiko Ui-Tei at the University of Tokyo.  Chimera RNAi has many advantages over the conventional siRNAs.  First, it has been demonstrated to have reliable knock-down for over 10,000 human genes.  Because the human genome is composed of an intricate, genetic network, chimera RNAis unique design has successfully obviated the off-target effects including microRNA-based influence.  Another advantage of the chimera RNAi technology is its effectiveness at low concentrations (0.5nM to 5nM); only mRNA is destroyed so genomic genes are not affected.  Finally, having both the sense and anti-sense strands consisting RNA/DNA chimera, it offers much greater compound stability for streamlining in vitro and in vivo assays and applications while minimizing interferon induction and other adverse reactions.

PMID: 23716627

Share this post on:

Author: Potassium channel